SCHEMBL13100657

SCHEMBL13100657

COc1cccc(C(=O)CC(C(=O)O)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.58
ADRA2A P08913 1/20 0.58
DRD1 P21728 1/20 0.58
SLC6A2 P23975 1/20 0.58
SLC6A4 P31645 1/20 0.58
ADRA1A P35348 1/20 0.58
OPRM1 P35372 1/20 0.58
DRD3 P35462 1/20 0.58
SLC6A3 Q01959 1/20 0.58
KCNH2 Q12809 1/20 0.58
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
HSD11B1 P28845 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.52
CES2 O00748 1/20 0.51
CES1 P23141 1/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
GPR139 Q6DWJ6 5/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11523072 0.90 HTR1A (0.57) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL7823381 0.90 KMT2A (0.70) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL9148324 0.84 L3MBTL1 (0.73) KMT2AMEN1L3MBTL1CES2CES1
SCHEMBL5161471 0.84 L3MBTL1 (0.64) KMT2AMEN1HSD11B1L3MBTL1CES2
SCHEMBL28629704 0.83 MAPT (0.69) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL12158740 0.82 L3MBTL1 (0.62) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL13100658 0.82 KMT2A (0.79) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL11203155 0.81 CES2 (0.56) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL6169730 0.81 CES2 (0.56) HTR1AADRA2ADRD1SLC6A2SLC6A4
SCHEMBL6645336 0.81 AKR1C3 (0.49) HTR1AADRA2ADRD1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256394-A1 METHOD FOR THE PREPARATION OF LASOFOXIFENE ZENTIVA K.S. (CZ) 2010-10-07 US disclosed
US-20100256394-A1 METHOD FOR THE PREPARATION OF LASOFOXIFENE ZENTIVA K.S. (CZ) 2010-10-07 US disclosed
WO-2008145075-A2 METHOD FOR THE PREPARATION OF LASOFOXIFENE AND CRYSTALLINE INTERMEDIATES USED THEREIN ZENTIVA, A.S. (CZ) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256394-A1 METHOD FOR THE PREPARATION OF LASOFOXIFENE SRD5A1, SRD5A2, CYP19A1 HTR1A 147/4885ADRA2A 1670/4885DRD1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.